Hasil Pencarian - Mark R Middleton

Perbaiki Hasil
  1. 1
    New treatment approaches in melanoma: current research and clinical prospects

    New treatment approaches in melanoma: current research and clinical prospects oleh Milap G. Rughani, Avinash Gupta, Mark R. Middleton

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

    Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series oleh Andrew J. Dooley, Avinash Gupta, Madhumita Bhattacharyya, Mark R. Middleton

    Diterbitkan 2014-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

    Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis oleh Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

    Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals oleh Liz Morrell, Sarah Wordsworth, Anna Schuh, Mark R. Middleton, Sian Rees, Richard W. Barker

    Diterbitkan 2018-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

    Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals oleh Liz Morrell, Sarah Wordsworth, Anna Schuh, Mark R. Middleton, Sian Rees, Richard W. Barker

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Societal preferences for adjuvant melanoma health states: UK and Australia

    Societal preferences for adjuvant melanoma health states: UK and Australia oleh Mark R. Middleton, Michael B. Atkins, Kaitlan Amos, Peter Feng Wang, Srividya Kotapati, Javier Sabater, Kathleen Beusterien

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

    Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma oleh Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

    Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in a... oleh Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

    712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell... oleh David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

    Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-labe... oleh Mark R Middleton, Winald R Gerritsen, Ian Walters, Licia Rivoltini, Niven Mehra, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Uzi Gileadi, Inka Pawlitzky, Konstantina Grosios, Petronella B Ottevanger

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

    A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma oleh Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton, Graham P. Collins

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer

    PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer oleh Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.

    Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis. oleh Pamela J Kaisaki, Anthony Cutts, Niko Popitsch, Carme Camps, Melissa M Pentony, Gareth Wilson, Suzanne Page, Kulvinder Kaur, Dimitris Vavoulis, Shirley Henderson, Avinash Gupta, Mark R Middleton, Ioannis Karydis, Ioannis Karydis, Denis C Talbot, Anna Schuh, Jenny C Taylor

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

    Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study oleh Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study oleh Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination

    Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination oleh Brian Shine, Robert Pell, Weiyu Ye, Mark R Middleton, Tim James, Stephanie Jones, Robert A Watson, Ian S D Roberts, Monika Hofer, Damian Jenkins, Miranda J Payne, Nicholas Coupe, Chelsea A Taylor, Elsita Jungkurth, Rosalin Cooper, Orion Tong, Eleni Ieremia, David Maldonado-Perez, Benjamin P Fairfax

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan

    Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan oleh Serigne N. Lo, Angela M. Hong, Lauren E. Haydu, Tasnia Ahmed, Elizabeth J. Paton, Victoria Steel, George Hruby, Anh Tran, Rachael L. Morton, Anna K. Nowak, Janette L. Vardy, Katharine J. Drummond, Haryana M. Dhillon, Catherine Mandel, Richard A. Scolyer, Mark R. Middleton, Bryan H. Burmeister, John F. Thompson, Gerald B. Fogarty

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial

    705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial oleh Dirk Schadendorf, Gino K In, Mark R Middleton, Mohammed Milhem, Adel Samson, Bartosz Chmielowski, Michael K Wong, Robert S Coffin, Trisha M Wise-Draper, Eva Muñoz-Couselo, Joseph J Sacco, Georgia M Beasley, Judith Michels, Praveen K Bommareddy, Katy K Tsai, Jeannie W Hou, Alina Monteagudo, Tawnya Lynn Bowles, Ari M VanderWalde, Jason Alan Chesney, Fade Mahmoud, Walter Hong, Aaron Clack

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer

    Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer oleh Paul C. Lyon, BSc, MSc, MRCS, MRes, DPhil, Helen Winter, BSc, MBBS, MSc, MRCP, FRACP, Karin Herbschleb, MRCP, Leticia Campo, Diploma, Robert Carlisle, PhD, Feng Wu, MD, PhD, Robert Goldin, MD, MEd, FRCPath, Constantin C. Coussios, PhD, Mark R. Middleton, BA, MA, PhD, FRCP, Fergus V. Gleeson, FRCR, FRCP, Philip Boardman, FRCR, Ricky A. Sharma, MB, BChir, MA, PhD, FRCP, FRCR

    Diterbitkan 2018-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes

    Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes oleh Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B. Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A. Scolyer, Pippa Corrie, David J. Adams, Alvis Brazma, Roy Rabbie

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: